Ascendis Pharma (ASND) total debt
Ascendis Pharma (ASND) carried total debt of €871.79M at the end of fiscal 2025 (December 31, 2025). That is 1.8% higher than the €856.62M of fiscal 2024. Figures as of 18 Nov 2026, 04:01 UTC, from Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- €871.79M
- Change on fiscal 2024
- +1.8%
- Highest on record
- €871.79Mfiscal 2025
- Lowest on record
- €508.38Mfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in EUR. Figures, not advice.
Ascendis Pharma total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was €871.79M in fiscal 2025 and the lowest €508.38M in fiscal 2022.
Total debt by fiscal year
Ascendis Pharma total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | €871.79M | 1.8% up | — | |
| 2024 | €856.62M | 33.0% up | — | |
| 2023 | €644.27M | 26.7% up | — | |
| 2022 | €508.38M | — | 1.9× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Revvity RVTY | $3.40B | 2025 |
| Exelixis EXEL | $173.04M | 2025 |
| Charles River Laboratories International CRL | $2.57B | 2025 |
| Neurocrine Biosciences NBIX | $415.30M | 2025 |
| Ascendis Pharma ASND | €871.79M | 2025 |
| ICON ICLR | $3.56B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Ascendis Pharma, figure by figure
- Ascendis Pharma market cap
- Ascendis Pharma revenue
- Ascendis Pharma earnings
- Ascendis Pharma earnings per share (EPS)
- Ascendis Pharma P/E ratio
- Ascendis Pharma P/S ratio
- Ascendis Pharma P/B ratio
- Ascendis Pharma free cash flow
- Ascendis Pharma operating margin
- Ascendis Pharma dividend
- Ascendis Pharma shares outstanding
- Ascendis Pharma cash on hand
- Ascendis Pharma total assets
- Ascendis Pharma return on equity (ROE)
- Ascendis Pharma return on invested capital (ROIC)
Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value
Ascendis Pharma total debt: questions and answers
How much debt does Ascendis Pharma have?
Ascendis Pharma (ASND) carried total debt of €871.79M at the end of fiscal 2025 (December 31, 2025). That is 1.8% higher than the €856.62M of fiscal 2024.
What are the highest and lowest total debt figures on record for Ascendis Pharma?
Across the 4 fiscal years on record (2022–2025), the highest was €871.79M in fiscal 2025 and the lowest €508.38M in fiscal 2022.
How is Ascendis Pharma's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Ascendis Pharma (ASND) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/ASND/total-debt
Underlying data: Yahoo Finance.